Kristin Lehmkemper

Kristin Lehmkemper

Auto-generated profile, based on publicly available information

Kristin Lehmkemper

AbbVie Deutschland GmbH & Co. KG, Global Pharmaceutical R&D, Knollstraße, D-67061 Ludwigshafen am Rhein, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
OHOliver Heinzerling
Oliver Heinzerling
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski

1 March 2018 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
MBMareike Bartels
Mareike Bartels
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski

28 May 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Stefanie Regina WalterStefanie Regina Walter
Stefanie Regina Walter
PRPhilipp Reimer
Philipp Reimer
CLChristian Lübbert
Christian Lübbert
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel O. Kyeremateng
Samuel O. Kyeremateng
GSGabriele Sadowski
Gabriele Sadowski

27 September 2021 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MAMohammad Atif Faiz Afzal
Mohammad Atif Faiz Afzal
KLKristin Lehmkemper
Kristin Lehmkemper
ESEkaterina Sobich
Ekaterina Sobich
THThomas F. Hughes
Thomas F. Hughes
DGDavid J. Giesen
David J. Giesen
JSJohn C. Shelley
John C. Shelley

2 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AKAdrian Krummnow
Adrian Krummnow
ADAndreas Danzer
Andreas Danzer
KVKristin Voges
Kristin Voges
SKSamuel Kyeremateng
Samuel Kyeremateng
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski
The poor bioavailability of an active pharmaceutical ingredient (API) can be enhanced by dissolving it in a polymeric matrix. This formulation strategy is commonly known as amorphous solid dispersion (ASD). API crystallization and/or amorphous phase separation can be detrimental to the bioavailability. Our previous work (Pharmaceutics 2022, 14(9), 1904) provided analysis of the thermodynamics underpinning the collapse of ritonavir (RIT) release from RIT/poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA) ASDs due to water-induced amorphous phase separation. This work aimed for the first time to quantify the kinetics of water-induced amorphous phase separation in ASDs and the compositions of the two evolving amorphous phases. Investigations were performed via confocal Raman spectroscopy, and spectra were evaluated using so-called Indirect Hard Modeling. The kinetics of amorphous phase separation were quantified for 20 wt% and 25 wt% drug load (DL) RIT/PVPVA ASDs at 25 °C and 94% relative humidity (RH). The in situ measured compositions of the evolving phases showed excellent agreement with the ternary phase diagram of the RIT/PVPVA/water system predicted by PC-SAFT in our previous study (Pharmaceutics 2022, 14(9), 1904).

25 May 2021 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
BLBo Liu
Bo Liu
FTFrank Theil
Frank Theil
KLKristin Lehmkemper
Kristin Lehmkemper
DGDavid Gessner
David Gessner
YLYanxia Li
Yanxia Li
HLHolger van Lishaut
Holger van Lishaut